ATS (ATS) AGM 2024 summary
Event summary combining transcript, slides, and related documents.
AGM 2024 summary
19 May, 2026Opening remarks and agenda
Meeting opened with a welcome, introduction of board and executive team, and emphasis on shareholder engagement.
Agenda included business updates, financial review, election of directors, auditor reappointment, and executive compensation advisory vote.
Financial performance review
Fiscal 2024 delivered record revenues of CAD 3 billion and adjusted earnings of CAD 398 million, with 18% revenue growth and 11% organic growth.
Order bookings reached CAD 2.9 billion, ending with a CAD 1.8 billion backlog; adjusted EBITDA margin was 15.5%.
Five-year compound annual revenue growth averaged 19.3%, with adjusted EBITDA growing 23.7% annually.
Cash from operations was CAD 21 million, with a free cash outflow of CAD 68 million; net debt to adjusted EBITDA at 2.4:1.
Board and executive committee updates
Board advanced ESG priorities, supported capital allocation strategies, and oversaw four acquisitions enhancing services, digitization, and AI capabilities.
Sustainability committee is now fully active, alongside Audit, Governance, HR, and Strategic Opportunities committees.
Latest events from ATS
- Board and auditor appointments approved; focus on value creation and growth initiatives.ATS
AGM 2026 - Revenues fell 5.8% and a net loss was posted as cost transformation and margin initiatives began.ATS
Q1 2027 - Margin expansion, portfolio diversification, and disciplined M&A drive future growth.ATS
47th Annual Raymond James Institutional Investor Conference - Life Sciences and digital services drive growth, with strong bookings and expanding recurring revenue.ATS
Citi's Global Industrial Tech and Mobility Conference 2025 - C$3.0B adjusted revenue, strong M&A, and disciplined growth in automation markets.ATS
Investor presentation - Revenue and earnings rose in fiscal 2026, with restructuring driving margin expansion.ATS
Q4 2026 - Flexible shelf offering supports growth in automation for regulated, high-value markets.ATS
Registration filing - Q2 revenue fell 17% as transportation slumped, but record life sciences bookings and a $1.8B backlog support growth.ATS
Q2 2025 - Record backlog and EV settlement set the stage for margin and leverage improvement.ATS
Q4 2025